125 results about "Polar lipids" patented technology

Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C₆-C₁₂ fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

Eicosapentaenoic acid (EPA) compositions and EPA-rich polar lipids for prophylactic or therapeutic applications are described. Production from certain cultured micro-organisms (like Nitzschia laevis) promotes synthesis of EPA, including polar lipids including EPA. The EPA-rich polar lipids themselves may be used as polar compounds. EPA can be selectively hydrolysed from particular positions in isolated polar lipids by lipase activity, then optionally further purified. The process bypasses reliance on diminishing fish stocks and on physico-chemical processes that may not adequately separate desirable n-3 HUFAs from unwanted products like DHA also found in fish oil and cultured organisms.

Methods, systems, and apparatuses for extracting non-polar lipids from microalgae are achieved using a lipid extraction device having an anode and a cathode that forms a channel and defines a fluid flow path through which an aqueous slurry is passed. An electromotive force is applied across the channel at a gap distance in a range from 0.5 mm to 200 mm to cause the non-polar lipids to be released from the algae cells. The non-polar lipids can be extracted at a high throughput rate and with low concentrations of polar lipids such as phospholipids and chlorophyll.

The production and use, and in particular, the extraction, separation, synthesis and recovery of polar lipid-rich fractions containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA(n-3) or DPA(n-6)), arachidonic acid (ARA), and eicosatetraneonoic acid (C20:4n-3) from microorganisms, genetically modified seeds and marine organisms (including fish and squid) and their use in human food applications, animal feed, pharmaceutical applications and cosmetic applications.

A method for separating polar lipids from plant material, in particular, intact algal cells, using an amphipathic solvent set and a hydrophobic solvent set. Some embodiments include dewatering intact algal cells and then extracting polar lipids from the algal cells. The methods provide for single and multistep extraction processes which allow for efficient separation of algal polar lipids from a wet algal biomass while avoiding emulsification of extraction mixtures. These polar lipids are high value products which can be used as surfactants, detergents, and food additives. Neutral lipids remaining in the algal biomass after extraction of polar lipids can be used to generate renewable fuels.

A method for separating neutral lipids from plant material, in particular, intact algal cells, using an amphipathic solvent set and a hydrophobic solvent set. Some embodiments include dewatering intact algal cells and then extracting neutral lipids from the algal cells. The methods provide for single and multistep extraction processes which allow for efficient separation of algal neutral lipids from a wet algal biomass while avoiding emulsification of extraction mixtures. The neutral lipids are removed after first removing a polar lipid fraction and a protein fraction. These neutral lipids can be used to generate renewable fuels as well as food products and supplements.

A method for separating polar lipids from plant material, in particular, intact algal cells, using an amphipathic solvent set and a hydrophobic solvent set. Some embodiments include dewatering intact algal cells and then extracting polar lipids from the algal cells. The methods provide for single and multistep extraction processes which allow for efficient separation of algal polar lipids from a wet algal biomass while avoiding emulsification of extraction mixtures. These polar lipids are high value products which can be used as surfactants, detergents, and food additives. Neutral lipids remaining in the algal biomass after extraction of polar lipids can be used to generate renewable fuels.

The invention relates to a culture-free biochemical method for analyzing the microbial community structure of yeast for traditional brewage, in particular to a method for analyzing the microbial community structure of yeast for traditional brewage by using the phospholipid fatty acid spectrogram analysis technique. The method comprises the following steps: (1) weighting a certain amount of yeast sample which is pulverized and evenly mixed; (2) adding a buffer solution and an organic reagent to obtain an organic phase containing lipids; (3) separating the organic phase by small silica gel columns, eluting and collecting organic components containing polar lipids; (4) carrying out methyl esterification under mild condition, and adding an extracting reagent to obtain corresponding fatty acid methyl ester; (5) carrying out quantitative analysis on the fatty acid methyl ester by using a gas chromatogram-mass spectrogram combined instrument; and (6) determining the characteristics of the microbial community structure in the sample according to characteristics of different phospholipid fatty acid compositions. The invention provides an accurate and quick culture-free detection means for researching the composition of the microbial community structure of yeast for brewage and knowing the law of growth and decline of different microbial communities in the yeast preparation process.

Methods and reagents are provided for specifically targeting biologically active compounds such as antiviral and antimicrobial drugs, or prodrugs containing the biologically active compound to specific sites such as specific organelles in phagocytic mammalian cells. The biologically active compound or prodrug is linked to a microparticle with a linker that is non-specifically or specifically cleaved inside a phagocytic mammalian cell. Alternatively, the biologically active compound or prodrug is impregnated into a porous microparticle or coated on a nonporous microparticle, and then coated with a coating material that is non-specifically or specifically degraded inside a phagocytic mammalian cell. The prodrug contains the biologically active compound linked to a polar lipid such as ceramide with a specific linker such as a peptide that is specifically cleaved to activate the prodrug in a phagocytic mammalian cell infected with a microorganism. A microparticle linked antimicrobial drug or prodrug may be used for killing a microorganism infecting a phagocytic mammalian cell in vivo or in vitro.

The present invention refers to pharmaceutical formulations based on lipids for ophthalmic use comprising a phospholipid component composed of zwitterionic phospholipids of natural origin and an oily component composed of oils of natural origin emulsified in water. In particular, the invention refers to ophthalmic formulations useful, for example, for transporting drugs to the eye and in the treatment of ocular dryness, capable of restoring the lipid layer of the tear film. In particular, in a non-transitory but pathological situation such as the dry eye syndrome, such formulations also succeed in reducing the often-present inflammatory component.

A method for converting lipids to alkyl esters may include receiving a reactant comprising one or more lipids. In some cases, the reactant may include substantial amounts of polar lipids and/or free fatty acids. Some reactants may be derived from photosynthetic organisms, such as algae and/or diatoms. The reactant may be mixed with an alcohol and a catalyst to form a mixture. The mixture may be heated, for example, to a temperature between 50 and 350 degrees Celsius, including between 80 and 220 degrees Celsius. Pressure may be controlled to be between 1 and 200 bar, including between 10 and 100 bar. At least a portion of the reactant may be converted to one or more alkyl esters. A biofuel may include alkyl esters made from lipids according to various methods.

There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.

The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a large lipid globule size. The composition can be used to prevent obesity and/or improve body composition later in life. Said lipid component comprises 10-50 wt % vegetable lipids, and the lipid globules have a volume-weighted diameter above 1.0 m and/or a diameter of 2-12 m in an amount of at least 45 vol %.

Processes for the simultaneous production of sterols and polar lipids, in which preparations of vegetable oil lecithin fractions are subjected to ultrafiltration and, on the one hand, the sterols in the permeate and, on the other hand, the polar lipids in the retentate are enriched. The permeate and retentate can subsequently be worked up by methods known per se.

A method for separating polar lipids and neutral lipids from plant material, in particular, intact algal cells, using an amphipathic solvent set and a hydrophobic solvent set. Some embodiments include dewatering intact algal cells and then extracting polar lipids and neutral lipids from the algal cells. The methods provide for single and multistep extraction processes which allow for efficient separation of algal polar lipids and neutral lipids from a wet algal biomass while avoiding emulsification of extraction mixtures. These polar lipids are high value products which can be used as surfactants, detergents, and food additives. These neutral lipids are also high value products which can be used to generate renewable fuels.